2,531
Views
35
CrossRef citations to date
0
Altmetric
Original Research

Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy

, , , , , , , , , , , , , & show all
Article: e1108511 | Received 06 Jul 2015, Accepted 09 Oct 2015, Published online: 29 Apr 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Elnaz Faghfuri, Farhad Pourfarzi, Amir Hossein Faghfouri, Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh & Behzad Baradaran. (2021) Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opinion on Biological Therapy 21:2, pages 201-218.
Read now
Carlo Iavarone, Derek T. O’hagan, Dong Yu, Nicolas F. Delahaye & Jeffrey B. Ulmer. (2017) Mechanism of action of mRNA-based vaccines. Expert Review of Vaccines 16:9, pages 871-881.
Read now

Articles from other publishers (33)

Simona Granata, Giovanni Stallone & Gianluigi Zaza. (2023) mRNA as a medicine in nephrology: the future is now. Clinical Kidney Journal 16:12, pages 2349-2356.
Crossref
Feng Lin, Emma Z. Lin, Misa Anekoji, Thomas E. Ichim, Joyce Hu, Francesco M. Marincola, Lawrence D. Jones, Santosh Kesari & Shashaanka Ashili. (2023) Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines. Journal of Translational Medicine 21:1.
Crossref
Dun Niu, Yaran Wu & Jiqin Lian. (2023) Circular RNA vaccine in disease prevention and treatment. Signal Transduction and Targeted Therapy 8:1.
Crossref
Jieun Han, Jaesung Lim, Chi-Pin James Wang, Jun-Hyeok Han, Ha Eun Shin, Se-Na Kim, Dooyong Jeong, Sang Hwi Lee, Bok-Hwan Chun, Chun Gwon Park & Wooram Park. (2023) Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy. Nano Convergence 10:1.
Crossref
Tian‐yi Zhang, Hang Xu, Xiao‐nan Zheng, Xing‐yu Xiong, Shi‐yu Zhang, Xian‐yanling Yi, Jin Li, Qiang Wei & Jian‐zhong Ai. (2023) Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis. MedComm 4:4.
Crossref
Steve Pascolo. (2023) Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history. European Journal of Immunology 53:7.
Crossref
Sung-Young Jung, Ji Youn Maeng, HyunJong Lee, Jeong Joon Han, Soung Min Kim & Hoon Myoung. (2023) Metastasis of Renal Cell Carcinoma to the Mandible. Journal of Craniofacial Surgery 34:4, pages e334-e336.
Crossref
Yingxue Mei & Xiang Wang. (2023) RNA modification in mRNA cancer vaccines. Clinical and Experimental Medicine.
Crossref
Shichao Zhang, Kaide Xia, Yue Chang, Yimei Wei, Yu Xiong, Fuzhou Tang, Jian Peng & Yan Ouyang. (2023) LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically ‘Cold’ KIRC Tumours. Vaccines 11:2, pages 396.
Crossref
Kamya Sankar, Jing Christine Ye, Zihai Li, Lei Zheng, Wenru Song & Siwen Hu-Lieskovan. (2022) The role of biomarkers in personalized immunotherapy. Biomarker Research 10:1.
Crossref
Lu Yang, Guangping Gao & Jiaoti Huang. (2022) Letter to the Editor: mRNA Vaccines in Urological Malignancies . Human Gene Therapy 33:19-20, pages 1101-1102.
Crossref
Tao Huang, Lushan Peng, Yingying Han, Dan Wang, Xiaoyun He, Junpu Wang & Chunlin Ou. (2022) Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Frontiers in Immunology 13.
Crossref
Yesim Eralp. (2022) Application of mRNA Technology in Cancer Therapeutics. Vaccines 10:8, pages 1262.
Crossref
Mia Karam & Georges Daoud. (2022) mRNA vaccines: Past, present, future. Asian Journal of Pharmaceutical Sciences 17:4, pages 491-522.
Crossref
Shugang Qin, Xiaoshan Tang, Yuting Chen, Kepan Chen, Na Fan, Wen Xiao, Qian Zheng, Guohong Li, Yuqing Teng, Min Wu & Xiangrong Song. (2022) mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy 7:1.
Crossref
Amanda L. Huff, Elizabeth M. Jaffee & Neeha Zaidi. (2022) Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. Journal of Clinical Investigation 132:6.
Crossref
Poonam R. Pandey, Ken H. Young, Dhiraj Kumar & Neeraj Jain. (2022) RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Molecular Cancer 21:1.
Crossref
Chengyan Jin, Yan Zhang, Guangxin Zhang, Bin Wang & Peiyan Hua. (2022) Combination of GNRs-PEI/cGAMP-laden macrophages-based photothermal induced in situ tumor vaccines and immune checkpoint blockade for synergistic anti-tumor immunotherapy. Biomaterials Advances 133, pages 112603.
Crossref
Joanna Bialek, Andreas Wencker, Felix Kawan, Stefan Yankulov, Paolo Fornara & Gerit Theil. (2022) Potential Use of CTCs as Biomarkers in Renal Cancer Patients. Life 12:1, pages 89.
Crossref
Hang Xu, Xiaonan Zheng, Shiyu Zhang, Xianyanling Yi, Tianyi Zhang, Qiang Wei, Hong Li & Jianzhong Ai. (2021) Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Molecular Cancer 20:1.
Crossref
Lei Miao, Yu Zhang & Leaf Huang. (2021) mRNA vaccine for cancer immunotherapy. Molecular Cancer 20:1.
Crossref
Marina Tusup, Severin Läuchli, Natalia Teresa Jarzebska, Lars E. French, Yun-Tsan Chang, Maya Vonow-Eisenring, Andreas Su, Thomas M. Kündig, Emmanuella Guenova & Steve Pascolo. (2021) mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma. Pharmaceutics 13:7, pages 1040.
Crossref
Annkristin Heine, Stefan Juranek & Peter Brossart. (2021) Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer 20:1.
Crossref
Steve Pascolo. (2021) Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. Viruses 13:2, pages 270.
Crossref
Sebastian P. Haen, Markus W. Löffler, Hans-Georg Rammensee & Peter Brossart. (2020) Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nature Reviews Clinical Oncology 17:10, pages 595-610.
Crossref
Elinor Willis, Norbert Pardi, Kaela ParkhouseBarbara L. MuiYing K. TamDrew Weissman & Scott E. Hensley. (2020) Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. Science Translational Medicine 12:525.
Crossref
Rein Verbeke, Ine Lentacker, Stefaan C. De Smedt & Heleen Dewitte. (2019) Three decades of messenger RNA vaccine development. Nano Today 28, pages 100766.
Crossref
Martin Sebastian, Andreas Schröder, Birgit Scheel, Henoch S. Hong, Anke Muth, Lotta von Boehmer, Alfred Zippelius, Frank Mayer, Martin Reck, Djordje Atanackovic, Michael Thomas, Folker Schneller, Jan Stöhlmacher, Helga Bernhard, Andreas Gröschel, Thomas Lander, Jochen Probst, Tanja Strack, Volker Wiegand, Ulrike Gnad-Vogt, Karl-Josef Kallen, Ingmar Hoerr, Florian von der Muelbe, Mariola Fotin-Mleczek, Alexander Knuth & Sven D. Koch. (2019) A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunology, Immunotherapy 68:5, pages 799-812.
Crossref
Zifu Zhong, Séan Mc Cafferty, Francis Combes, Hanne Huysmans, Joyca De Temmerman, Arlieke Gitsels, Daisy Vanrompay, João Portela Catani & Niek N. Sanders. (2018) mRNA therapeutics deliver a hopeful message. Nano Today 23, pages 16-39.
Crossref
Sandra Scheiblhofer, Josef Thalhamer & Richard Weiss. (2018) DNA and mRNA vaccination against allergies. Pediatric Allergy and Immunology 29:7, pages 679-688.
Crossref
Matthias A. Oberli, Andreas M. Reichmuth, J. Robert Dorkin, Michael J. Mitchell, Owen S. Fenton, Ana Jaklenec, Daniel G. Anderson, Robert Langer & Daniel Blankschtein. (2016) Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Letters 17:3, pages 1326-1335.
Crossref
Christian Grunwitz & Lena M. Kranz. 2017. Cancer Vaccines. Cancer Vaccines 145 164 .
Shichao Zhang, Yu Xiong, Shijing Kang, Chengju Mao, Zhu Zeng, Jian Peng & Yan Ouyang. (2021) LRP2 and DOCK8 are Potential Antigens for mRNA Vaccine Development in Immunologically ‘Cold’ KIRC Tumours. SSRN Electronic Journal.
Crossref